Efficacy and Safety of Systemic Therapies Following Progression on CDK4/6 Inhibitors in Patients with HR+/HER2-- Metastatic Breast Cancer: A Systematic Review and Network Meta-Analysis
Roberto Buonaiuto(Scuola Superiore Meridionale), Carmine De Angelis(Baylor College of Medicine), Angela Grieco(University of Naples Federico II), Claudio Vernieri(Fondazione IRCCS Istituto Nazionale dei Tumori), Aldo Caltavituro(University of Naples Federico II), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Maria Letizia Cataldo(Baylor College of Medicine), Andrea Botticelli(Sapienza University of Rome), Paolo Chiodini(University of Campania "Luigi Vanvitelli"), Mario Fordellone(University of Campania "Luigi Vanvitelli"), Lorenzo Gerratana(National Cancer Institute), Mario Giuliano(Regione Campania), Alessandra Longobardi(Federico II University Hospital), Luca Malorni(Azienda Usl Toscana Centro), Antonio Giordano(Harvard University), Maria Vittoria Dieci(University of Padua), Matteo Lambertini(Ospedale Policlinico San Martino), Roberta Caputo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Federica P. Mangiacotti(Federico II University Hospital), Carmen Criscitiello(University of Milan), Maria Grazia Arpino(University of Naples Federico II), Martina Pagliuca(Institut Gustave Roussy)
Cited by 0
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
|Journal of Clinical Oncology|2007|413